The Clinical Picture and Plasma Levodopa Metabolite Profile of Parkinsonian Nonresponders

Authors:
  • LRLeonor Rivera-Calimlim
    Leonor Rivera-Calimlim
  • DTDeepak Tandon
    Deepak Tandon
  • FAFrank Anderson
    Frank Anderson
  • RJRobert Joynt
    Robert Joynt

Abstract
• Three parkinsonian patients who were nonresponders to levodopa treatment did not improve when shifted to levodopa-decarboxylase inhibitor combination but, instead, experienced involumtary movements. Their plasma levodopa and metabolite profiles showed unusually high baseline 3-0-methyldopa concentrations that further increased significantly during the decarboxylase inhibitor regimen. All patients had 3-0-methyldopa to levodopa ratios greater than 1, even two hours after therapy. Patients who are responders to levodopa-decarboxylase inhibitor combination or to levodopa alone had 3-0-methyldopa to levodopa ratios of less than 1. We discuss the role of 3-0-methyldopa as a metabolite and the significance of the 3-0-methyldopa to levodopa ratio as a predictor of patients' response to levodopa.

This publication has 8 references indexed in Scilit: